2.73
1.09%
-0.03
アフターアワーズ:
2.29
-0.44
-16.12%
前日終値:
$2.76
開ける:
$2.74
24時間の取引高:
7,229
Relative Volume:
0.04
時価総額:
$142.42M
収益:
$18.85M
当期純損益:
$-119.67M
株価収益率:
-1.3436
EPS:
-2.0318
ネットキャッシュフロー:
$-89.09M
1週間 パフォーマンス:
+1.87%
1か月 パフォーマンス:
+45.87%
6か月 パフォーマンス:
-17.27%
1年 パフォーマンス:
-30.00%
Inventiva Adr Stock (IVA) Company Profile
Inventiva Adr Stock (IVA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-10-27 | 開始されました | Canaccord Genuity | Buy |
2023-05-31 | 開始されました | ROTH MKM | Buy |
2023-05-19 | アップグレード | Societe Generale | Sell → Buy |
2023-03-17 | 開始されました | Stifel | Buy |
2022-11-15 | ダウングレード | Societe Generale | Buy → Sell |
2021-03-08 | ダウングレード | Societe Generale | Buy → Sell |
2020-08-05 | 開始されました | ROTH Capital | Buy |
2020-08-04 | 開始されました | Guggenheim | Buy |
2020-08-04 | 開始されました | Stifel | Buy |
すべてを表示
Inventiva Adr (IVA) 最新ニュース
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH - GlobeNewswire Inc.
Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Inventiva ADR (IVA) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Why Are Criminals Still in Power? 151 Lawmakers with Charges of Crimes Against Women Continue to Hold Office! Is This the End of Integrity in Indian Politics? - Inventiva
Why Paramount Global Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving PremarketParamount ... - Benzinga
Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and ... - GlobeNewswire Inc.
Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA) - Yahoo Finance
Assemblée Générale Mixte du 20 juin 2024 - GlobeNewswire Inc.
Inventiva's Key Drug Trial Advances PositivelyTipRanks.com - TipRanks
Inventiva SA ADR Announces Key General MeetingTipRanks.com - TipRanks
Inventiva's Lanifibranor Shows Promise in MASH/NASH TreatmentTipRanks.com - TipRanks
Inventiva announces the implementation of an At-The-Market program in the United States - The Globe and Mail
Inventiva's Latest Move: Issuing Royalty Certificates That Could Dilute Lanifibranor EarningsTipRanks.com - TipRanks
Will Election Commission Make Sure That Elections In 2024 Will Be Completely Fair? - Inventiva
Inventiva SA ADR Announces Optimistic 2023 ResultsTipRanks.com - TipRanks
Inventiva’s LEGEND Trial Shows Promising Results - TipRanks
Is SBI's Demand For Extra Time To Disclose Details Of Electoral Bonds 1 Attempt To Hide The Doings And Doers Of ‘Great Political Chanda’? - Inventiva
IVA Stock Quote Price and Forecast - CNN
Supreme Court To Hear Plea Against Electoral Bonds From October 31 - Inventiva
National Parties Declare Assets Worth Rs 8,829 Crore In 2021-22: Report - Inventiva
Explosive Showdown: Rahul Yadav-Led 4B Networks Clash with Info Edge in High-Stakes Arbitration Battle - Inventiva
The Indian Chief Ministers Are A Bunch Of Crorepatis While The Average Middle-Class Indian Tax Payer Is Struggling To Survive - Inventiva
Top 10 Best Health & Wellness Companies In USA 2023 - Inventiva
Top 20 Best Hardware & Networking Company In India 2023 - Inventiva
Top 10 Best Law Firms In India 2023. - Inventiva
Top 10 Best LegalTech companies in India 2023 - Inventiva
An Interesting Telecom Startup Announced Funding Of INR 30 Crore - Inventiva
TCS, Infosys, Wipro Hire Over 1 Lakh Employees This Fiscal. Know Details - Inventiva
8 US equities have commenced trading on the NSE IFSC in GIFT City; All information about how to start trading through IFSC and should you put money in US stocks? - Inventiva
Innovation And Technology Revolutionizing The Legal Landscape In India 2022 - Inventiva
India Has Its First Most Awaited International Arbitration Centre In Hyderabad In 2021. - Inventiva
The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa - Yahoo Finance
The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer I - Benzinga
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Markets Insider
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent - Yahoo Finance
Inventiva Adr (IVA) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):